Use case
When BJ lacks a single disease label, start with standardized viability/phenotype assays, then refine from project literature.
In one line
Stable culture → seed → treatment grid → viability/molecular readouts.
Protocol overview
- 01Expand; log passage
- 02Seed and stabilize
- 03Treat with controls
- 04Harvest at endpoint
- 05Viability or molecular assays
- 06Independent repeats
- 01Expand; log passage; mycoplasma check.
- 02Seed and stabilize.
- 03Apply treatments with vehicle/positive controls.
- 04Endpoint viability, targets, or phenotypes.
- 05Compare vs controls; replicate key findings.
- 06Fix serum lot and passage window.
- 07Do not overclaim as a specific in vivo disease model.
- 08RUO.
Reagents / compounds
| Name | Role | Conc. |
|---|---|---|
| Test compound / inhibitor | Drug response or pathway intervention | 对数梯度;按文献与预实验优化 |
| Vehicle control (e.g. DMSO) | Rule out vehicle artifacts | 与最高药组等体积分数 |
| Viability reagent (MTT / CCK-8 / CTG) | Quantify viability/metabolic activity | 按试剂盒说明书 |
Readouts
Viability, molecular targets, morphology as needed.
Literature & manuals
- [1]PubMedPMID 1328042Immunology · 1992A cytotoxic rabbit T-cell line infected with a gamma-herpes virus which expresses CD8 and class II antigens.
- [2]PubMedPMID 6606682J Immunol Methods · 1983Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
- [3]PubMedPMID 17546025Cell Adh Migr · 2007An introduction to the wound healing assay using live-cell microscopy.